Investigational Drug Details
| Drug ID: | D043 |
| Drug Name: | Bismuth subcitrate |
| Synonyms: | Bismuth subcitrate potassium anhydrous |
| Type: | Chemical drug |
| DrugBank ID: | DB09275 |
| DrugBank Description: | A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD). |
| PubChem ID: | 10101269 |
| CasNo: | 57644-54-9 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [K].C(CC(=O)O)(CC(=O)O)(C(=O)O)O.[Bi] |
| Structure: |
|
| InChiKey: | ZBCVUEHBBZTSOB-UHFFFAOYSA-N |
| Molecular Weight: | -- |
| DrugBank Targets: | ATP-dependent Clp protease ATP-binding subunit ClpX antagonist |
| DrugBank MoA: | Colloidal bismuth subcitrate is very effective in the treatment of gastroduodenal disorders and appears to act via several mechanisms. It has little acid-neutralizing effect and does not affect acid secretion. It is uncertain whether it affects pepsin secretion, but it does inhibit peptic activity. It causes an increase in mucus glycoprotein secretion and may also bind to the gastric mucus layer to act as a diffusion barrier to HCl. It accelerates ulcer healing and causes an accumulation of epidermal growth factor around the ulcer. In addition, it has a cytoprotective effect and increases mucosal secretion of prostaglandins and bicarbonate. It has bactericidal effects against Helicobacter pylori (which is associated with gastritis and peptic ulcers). It also prevents adhesion of H. pylori to epithelial cells and can inhibit enzymes secreted by H. pylori, such as proteases, lipases, glycosidases, and phospholipases. |
| DrugBank Pharmacology: | Bismuth subcitrate is very effective in the treatment of gastroduodenal disorders and appears to act via several mechanisms. It has little acid-neutralizing effect and does not affect acid secretion. |
| DrugBank Indication: | For the treatment of peptic ulcer and gastro-oesophageal reflux disease (GORD). Treatment of inflammatory and erosive-ulcerous diseases of gastric and duodenal mucosa: gastritis, ulcer disease of the stomach and duodenum, functional non-ulcerous dyspepsia, erosive duodenitis, post-operative inflammatory and erosive changes – anastomositis, peptic ulcer of anastomosis |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 completed (NCT01876108) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0116 | NCT01876108 | Phase 2 | Completed | No Results Available | July 2012 | July 8, 2013 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Article ID | PMID | Source | Title |
|---|